A Systematic Review of Epigenetic Biomarkers in Progression from Non-dysplastic Barrett's Oesophagus to Oesophageal Adenocarcinoma

Overview

Journal BMJ Open

Specialty General Medicine

Date 2018 Jul 2

PMID 29961009

Citations 4

Authors

Tom Nieto

Claire L Tomlinson

Janine Dretzke

Susan Bayliss

Malcolm James Price

Mark Dilworth

Andrew D Beggs

Olga Tucker

Affiliations

Soon will be listed here.

Abstract

Objectives: The objective of this systematic review is to identify and summarise studies which examine epigenetic biomarkers in patients with Barrett's oesophagus (BO) and their association with progression to oesophageal adenocarcinoma (OADC). BO is a precursor lesion for OADC. There is no clinical test to predict patients who are likely to progress to OADC. An epigenetic biomarker could predict patients who are at high risk of progression from BO to OADC which could facilitate earlier diagnosis and spare those unlikely to develop cancer from regular invasive surveillance endoscopy.

Setting: A systematic search was conducted of the following databases: MEDLINE, MEDLINE in Process, EMBASE, Cochrane Central, ISI Conference Proceedings Citation Index and the British Library's ZETOC. Studies were conducted in secondary and tertiary care settings.

Participants: All studies measuring epigenetic change in patients over 18 years old who progressed from non-dysplastic BO to OADC were included. Genetic, in vitro and studies which did not measure progression in the same patient cohort were excluded. Study inclusion and risk of bias of individual eligible studies were assessed in duplicate by two reviewers using a modified Quality in Prognostic Studies tool.

Results: 14 studies met the inclusion criteria. 42 epigenetic markers were identified, and 5 studies developed models aiming to predict progression to OADC.

Conclusions: The evidence from this systematic review is suggestive of a role for p16 as an epigenetic biomarker for the progression of BO to OADC.

Prospero Number: CRD42016038654.

Citing Articles

Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy.

Schmidt M, Hackett R, Baker A, McDonald S, Quante M, Graham T Nat Rev Gastroenterol Hepatol. 2021; 19(2):95-111.

PMID: 34728819 DOI: 10.1038/s41575-021-00531-4.

Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma: Implications for Screening and Surveillance.

Cook M, Thrift A Gastrointest Endosc Clin N Am. 2020; 31(1):1-26.

PMID: 33213789 PMC: 7887893. DOI: 10.1016/j.giec.2020.08.001.

Molecular biomarker identification for esophageal adenocarcinoma using endoscopic brushing and magnified endoscopy.

Goda K, Murao T, Handa Y, Katsumata R, Fukushima S, Nakato R Esophagus. 2020; 18(2):306-314.

PMID: 32728973 DOI: 10.1007/s10388-020-00762-5.

Towards screening Barrett's oesophagus: current guidelines, imaging modalities and future developments.

Maitra I, Date R, Martin F Clin J Gastroenterol. 2020; 13(5):635-649.

PMID: 32495144 PMC: 7519897. DOI: 10.1007/s12328-020-01135-2.

References

Sauerbrei W . Prognostic factors. Confusion caused by bad quality design, analysis and reporting of many studies. Adv Otorhinolaryngol. 2004; 62:184-200. DOI: 10.1159/000082508. View

Shaheen N, Falk G, Iyer P, Gerson L . ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol. 2015; 111(1):30-50. PMC: 10245082. DOI: 10.1038/ajg.2015.322. View

Haggitt R, Tryzelaar J, Ellis F, COLCHER H . Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol. 1978; 70(1):1-5. DOI: 10.1093/ajcp/70.1.1. View

Nicholson A, Kuper H, Hemingway H . Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J. 2006; 27(23):2763-74. DOI: 10.1093/eurheartj/ehl338. View

Solaymani-Dodaran M, Logan R, West J, Card T, Coupland C . Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut. 2004; 53(8):1070-4. PMC: 1774141. DOI: 10.1136/gut.2003.028076. View

Wang Y, Wang Q, Zhang N, Ma H, Gu Y, Tang H . Identification of microRNAs as novel biomarkers for detecting esophageal squamous cell carcinoma in Asians: a meta-analysis. Tumour Biol. 2014; 35(11):11595-604. DOI: 10.1007/s13277-014-2350-x. View

Shaheen N, Sharma P, Overholt B, Wolfsen H, Sampliner R, Wang K . Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009; 360(22):2277-88. DOI: 10.1056/NEJMoa0808145. View

Boerwinkel D, di Pietro M, Liu X, Shariff M, Lao-Sirieix P, Walker C . Endoscopic TriModal imaging and biomarkers for neoplasia conjoined: a feasibility study in Barrett's esophagus. Dis Esophagus. 2012; 27(5):435-43. DOI: 10.1111/j.1442-2050.2012.01428.x. View

Herman J, Graff J, Myohanen S, Nelkin B, Baylin S . Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93(18):9821-6. PMC: 38513. DOI: 10.1073/pnas.93.18.9821. View

10.

Osborn N, Zou H, Molina J, Lesche R, Lewin J, Lofton-Day C . Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasia. Clin Gastroenterol Hepatol. 2006; 4(2):212-8. DOI: 10.1016/j.cgh.2005.11.009. View

11.

Ntzani E, Ioannidis J . Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet. 2003; 362(9394):1439-44. DOI: 10.1016/S0140-6736(03)14686-7. View

12.

Fitzgerald R, di Pietro M, Ragunath K, Ang Y, Kang J, Watson P . British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2013; 63(1):7-42. DOI: 10.1136/gutjnl-2013-305372. View

13.

Pidsley R, Zotenko E, Peters T, Lawrence M, Risbridger G, Molloy P . Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biol. 2016; 17(1):208. PMC: 5055731. DOI: 10.1186/s13059-016-1066-1. View

14.

Klump B, Hsieh C, Holzmann K, Gregor M, Porschen R . Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology. 1998; 115(6):1381-6. DOI: 10.1016/s0016-5085(98)70016-2. View

15.

Moinova H, Leidner R, Ravi L, Lutterbaugh J, Barnholtz-Sloan J, Chen Y . Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies. Cancer Epidemiol Biomarkers Prev. 2012; 21(4):594-600. PMC: 3454489. DOI: 10.1158/1055-9965.EPI-11-1060. View

16.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

17.

Kyzas P, Loizou K, Ioannidis J . Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst. 2005; 97(14):1043-55. DOI: 10.1093/jnci/dji184. View

18.

Overholt B, Lightdale C, Wang K, Canto M, Burdick S, Haggitt R . Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005; 62(4):488-98. DOI: 10.1016/j.gie.2005.06.047. View

19.

Nobori T, Miura K, Wu D, Lois A, Takabayashi K, Carson D . Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994; 368(6473):753-6. DOI: 10.1038/368753a0. View

20.

Barrett M, Sanchez C, Prevo L, Wong D, Galipeau P, Paulson T . Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet. 1999; 22(1):106-9. PMC: 1559997. DOI: 10.1038/8816. View